WHO treatment guidelines for drug-resistant tuberculosis 2016 update
The WHO treatment guidelines for drug-resistant tuberculosis (2016 update) contains policy recommendations on priority areas in the treatment of drug-resistant tuberculosis. The revision is in accordance with the WHO requirements for the formulation of evidence-informed policy. The main novelties of...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Geneva, Switzerland
World Health Organization
[2016], 2016
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The WHO treatment guidelines for drug-resistant tuberculosis (2016 update) contains policy recommendations on priority areas in the treatment of drug-resistant tuberculosis. The revision is in accordance with the WHO requirements for the formulation of evidence-informed policy. The main novelties of the 2016 WHO guidelines are: shorter MDR-TB treatment regimen is recommended under specific conditions; medicines used in the design of conventional MDR-TB treatment regimens are now reclassified to reflect updates in the evidence on their effectiveness and safety; specific recommendations are made on the treatment of children with rifampicin-resistant or MDR-TB based on a first-ever individual patient data meta-analysis; recommendations on the role of surgery in MDR-TB case management are included |
|---|---|
| Item Description: | "The End TB Strategy.". - "WHO/HTM/TB/2016.04"--PDF t.p. verso. - Preceded by Guidelines for the programmatic management of drug-resistant tuberculosis / World Health Organization. 2011 |
| Physical Description: | 1 PDF file (iv, 56 pages) |
| ISBN: | 9789241549639 |